Last reviewed · How we verify
NCT04851223
Investigating Plasma Biomarker Molecules Associated With the Progression of Prediabetes to Overt Type 2 Diabetes
trial in Type2 Diabetes Mellitus in 130 participants. Status unknown.
22 June 2023
Quick facts
| Lead sponsor | University of Roehampton |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 22 March 2021 |
| Primary completion | 22 June 2023 |
| Estimated completion | 22 September 2023 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Type2 Diabetes Mellitus — all drugs for Type2 Diabetes Mellitus →
- Pre Diabetes — all drugs for Pre Diabetes →
Sponsor
University of Roehampton
Who can join
Adults 18 to 65, any sex, with Type2 Diabetes Mellitus or Pre Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are an estimate 7 million people in the United Kingdom living with pre-diabetes. The increasing number of new cases of pre-diabetes presents a global health concern due to funding implications. The progression from pre-diabetes to overt type 2 diabetes is often characterised by a reduction in insulin secretion (or β-cell dysfunction). Whilst inflammation may contribute to β-cell dysfunction, a complete picture is still lacking. The proposed research will help develop a more complete understanding of the molecules that may trigger β-cell failure, a process that often connects pre-diabetes to overt diabetes. The aims of this project are; 1. Run large-scale proteomics and metabolomics analysis in pre-diabetic individuals to determine possible biomarker molecules. 2. Use measures and / or classifications of insulin resistance and diabetes (i.e. β-cell function and Disposition Index) to establish whether particular metabolic and / or proteomic signatures (aim 1) are associated with the development of pre-diabetes. 3. To determine if the possible metabolite or protein profile changes are associated with the progression or regression of pre-diabetes from baseline (0 month) to the end of the National Diabetes Prevention Programme (NDPP) (9 month).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04851223
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07533604 — SnapDandCGMinType2Diabetes · NA · recruiting
- NCT06961019 — Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets · NA · recruiting
- NCT06497842 — Effort During Resistance Training in Type 2 Diabetes · NA · active not recruiting
- NCT06257966 — A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type · Phase 3 · active not recruiting
- NCT03647306 — Behavioral Chronotype: Impact on Sleep and Metabolism · NA · active not recruiting
Other University of Roehampton trials
Trials by the same sponsor.
- NCT07042009 — Effectiveness of Nutritional Resources for Milk Donors · NA · not yet recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07436117 — Evaluating the Impact AI Avatar-led Mental Health Interventions for Keeping Employees in Work · NA · recruiting
- NCT06333223 — Polyphenols and Probiotics to Improve Menopausal Symptoms Via the Gut-Brain Axis · NA · recruiting
- NCT06147323 — Impact of High Fiber and Vegetal Protein Diet on Gut Health and Immunity Biomarkers in Prediabetic Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04851223 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Roehampton
- Last refreshed: 18 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04851223.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing